- Home
- Latest
- By speciality
- Policy
- Biology
- Bone
- Brain and nervous system
- Breast
- Colorectal and gastrointestinal
- Community
- Diagnostics
- Drug development
- Epidemiology and prevention
- Haematology oncology
- Head and neck
- Hepatobiliary pancreatic
- Lung and pleura
- Melanoma and skin
- Ovary and gynaecology
- Paediatric
- Prostate and urology
- Psycho social
- Radiotherapy
- Sarcomas
- Surgery
- Other
- By congress
- By continent
- Latest technologies
- Education
- Most viewed
- View all
Antibodies, Bristol-Myers Squibb , Cell therapy, Drug development, Drugs in development...
Flash player required
You do not have the correct version of the flash player required to view this content. Click here to install the free Adobe flash player.
Prof Alexander Eggermont - President of the European CanCer Organisation
A new era of melanoma treatment
Prof Alexander Eggermont, President of the European CanCer Organisation, talks to Editor Gordon McVie about a new era of melanoma treatment, immunomodulation, combination immunotherapy, ipilimumab's unprecedented success in increasing the 2 year survival rate, the EORTC 18071 trial, BRAF mutations, ECCO's lifetime achievement award and his initiative of 'oncopolicy'.
Specialities
- Policy (10)
- Biology (62)
- Bone (24)
- Brain and nervous system (14)
- Breast (190)
- Colorectal and gastrointestinal (43)
- Community (83)
- Diagnostics (37)
- Drug development (85)
- Epidemiology and prevention (53)
- Haematology oncology (60)
- Head and neck (17)
- Hepatobiliary pancreatic (17)
- Lung and pleura (47)
- Melanoma and skin (27)
- Ovary and gynaecology (33)
- Paediatric (17)
- Prostate and urology (42)
- Psycho social (19)
- Radiotherapy (27)
- Sarcomas (15)
Content is the view and comment of the speakers or author and not of sponsoring companies or organisations. Organisation logo does not indicate endorsement.
Comments on this video Report unsuitable comment
No comments have been made on this video yet, be the first to voice your opinion, use the form on the right.
Add a comment